boehringer ingelheim announced that starting June 1, all inhaler products will be capped at $35 per month. This is aimed at patients with employer-sponsored insurance and the underinsured and uninsured.
This comes about two months after Democratic senators sent their report. letter To America’s top inhaler manufacturer — AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline and Teva — as part of an investigation into the “exorbitant” prices of inhalers.
“We want to do our part to help patients with COPD and asthma who are struggling to pay for their medications. We support patients at an affordable price,” Jean-Michel Boas, president and CEO of Boehringer Ingelheim’s U.S. operations, said in a statement.
Boehringer Ingelheim’s main asthma products are: Spiriva® Respimat®a long-acting bronchodilator that can be used in combination with corticosteroids in cases of severe asthma.
Sen. Bernie Sanders (D-Vermont) welcomed the announcement, saying: Companies can do the same. ”
This movement is insulin maker last year. Sanofi, Novo Nordisk, and Eli Lilly have all launched similar programs that limit patients’ out-of-pocket costs to $35 per month for certain insulin products.
